Patents by Inventor Xuemin ZHAO

Xuemin ZHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11967312
    Abstract: This application provides a method for training a semantic understanding model, including: obtaining a first training sample set; performing denoising processing on the first training sample set to form a corresponding second training sample set; processing the second training sample set by using a semantic understanding model, to determine initial parameters of the semantic understanding model; processing the second training sample set by using the semantic understanding model in response to the initial parameters of the semantic understanding model, to determine update parameters of the semantic understanding model; and iteratively updating a semantic representation layer network parameter and a task-related output layer network parameter of the semantic understanding model by using the second training sample set and according to the update parameters of the semantic understanding model.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: April 23, 2024
    Assignee: TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
    Inventors: Gang Yuan, Xuemin Zhao
  • Publication number: 20220416236
    Abstract: The present disclosure discloses a W-containing high-nickel ternary cathode material, including both spherical secondary particles and single-crystal particles. There is basically no W inside the single-crystal particles, and the spherical secondary particles are doped with W.
    Type: Application
    Filed: June 30, 2020
    Publication date: December 29, 2022
    Inventors: Changxuan KE, Xuemin ZHAO, Mengyuan LI, Yulei HE, Xinxin TAN, Xu LI
  • Publication number: 20220387435
    Abstract: The present invention provides use of a multi-target protein kinase inhibitor compound A or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating leukemia, and provides a method for treating acute myeloid leukemia, especially acute myeloid leukemia with FLT3 mutation, with compound A. In clinical trials, compound A has certain efficacies both on acute myeloid leukemia with FLT3-ITD mutation and/or FLT3-TKD mutation, and on DEK-CAN positive acute myeloid leukemia with FLT3-ITD mutation. Patients with relapsed and/or refractory acute myeloid leukemia who have failed treatment previously with Type II FLT3 inhibitors (e.g., sorafenib) can still clinically benefit from the treatment with compound A.
    Type: Application
    Filed: November 9, 2020
    Publication date: December 8, 2022
    Applicant: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
    Inventors: Yueying Peng, Guoning Zhan, Xiaojing Li, Chunyan Hao, Xuemin Zhao, Wei Hu
  • Publication number: 20220036890
    Abstract: This application provides a method for training a semantic understanding model, including: obtaining a first training sample set; performing denoising processing on the first training sample set to form a corresponding second training sample set; processing the second training sample set by using a semantic understanding model, to determine initial parameters of the semantic understanding model; processing the second training sample set by using the semantic understanding model in response to the initial parameters of the semantic understanding model, to determine update parameters of the semantic understanding model; and iteratively updating a semantic representation layer network parameter and a task-related output layer network parameter of the semantic understanding model by using the second training sample set and according to the update parameters of the semantic understanding model.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Inventors: Gang YUAN, Xuemin ZHAO